Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI). (16th April 2022)

• Record Type: Journal Article
• Authors: Stirrup, Oliver; Krutikov, Maria; Tut, Gokhan; Palmer, Tom; Bone, David; Bruton, Rachel; Fuller, Chris; Azmi, Borscha; Lancaster, Tara; Sylla, Panagiota; Kaur, Nayandeep; Spalkova, Eliska; Bentley, Christopher; Amin, Umayr; Jadir, Azar; Hulme, Samuel; Giddings, Rebecca; Nacer-Laidi, Hadjer; Baynton, Verity; Irwin-Singer, Aidan; Hayward, Andrew; Moss, Paul; Copas, Andrew; Shallcross, Laura
• Is Part Of: Journal of infectious diseases. Volume 226:Number 11(2022)
• Page Start: 1877
• Page End: 1881
• Publication Date: 2022-04-16
• Subjects: COVID-19 -- long-term care facilities -- vaccination -- antibodies -- waning; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiac146
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: General population studies have shown strong humoral response following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination with subsequent waning of anti-spike antibody levels. Vaccine-induced immune responses are often attenuated in frail and older populations, but published data are scarce. We measured SARS-CoV-2 anti-spike antibody levels in long-term care facility residents and staff following a second vaccination dose with Oxford-AstraZeneca or Pfizer-BioNTech. Vaccination elicited robust antibody responses in older residents, suggesting comparable levels of vaccine-induced immunity to that in the general population. Antibody levels are higher after Pfizer-BioNTech vaccination but fall more rapidly compared to Oxford-AstraZeneca recipients and are enhanced by prior infection in both groups. Abstract : Antibody responses to vaccination in older residents of long-term care facilities are comparable to those in the general population. Although antibody levels are initially greater, they fall more rapidly following Pfizer-BioNTech vaccination than Oxford-AstraZeneca. Prior infection enhances responses in both groups.